Intel and cell research company Evotec Technologies are working together to develop and implement innovative technologies for faster results and cost reductions in pharmaceutical research.

The cooperation between the two companies focuses at the continued development of the Acapella cell analysis software from Evotec Technologies, which gains additional performance on the basis of the newest and most powerful Intel processors.

The influence of active ingredients on the behavior of cells is a core focus in pharmaceutical research. The Opera cell analyser from Evotec Technologies is an internationally renowned flagship product in cell analysis.

For the layman, the device is best compared to a high-power microscope that combines the high resolution of confocal laser scanning microscopy with an ultra-high throughput of over 200 000 images per day. The previously unmatched high speed and extremely high data quality offer an intelligent solution for test development, screening, and high turnover biology laboratories.

The images recorded with the cell analyser are evaluated with the help of the data analysis software Acapella, which generally offers a very wide range of methods for the evaluation of scientific data. In connection with this, thousands of images – an immense amount of data – must be processed in the shortest possible time. This demands very high performance from the Intel-based systems on which the software is running since May 2006.

Together with experts from the Intel Software Solutions Group (SSG), the specialists at Evotec Technologies are currently working on a higher-performance version of Acapella that will most likely be presented by the end of the year.

The improvements to the new version are particularly based on the change to the Intel Core architecture. If Acapella is running on the corresponding Intel dual or quad core systems, the user will be able to completely exhaust the performance potential of the future software version.

This provides cost savings of up to several ten thousands of Euros per screening campaign and an increase in evaluation turnover times by up to a factor of 10. Finally, the patients profit from earlier availability of advanced medicine at lower prices.